Immunostainings of CRC samples from short-term survivors show a strong expression of TIGIT in intra-tumoral immune cells, scattered within the cancer and lymphoid structures, but also in fibroblast-like stromal cells, resulting in a robust barrier against immune attack. Here, TIGIT is linked to colorectal carcinoma.